Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in chronic urticaria with anti-thyroid peroxidase IgE
2006-005404-13Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic urticaria (CU) comparing Omalizumab (Xolair) with Placebo (2 arms). Primary endpoint: UAS7 at study end. Started Dec 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on 2006-005404-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005404-13.